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Abstract
The C–H indolation of heteroarenes was realized using the benziodoxolone hypervalent iodine reagents indoleBXs. Functionaliza-
tion of the C–H bond in bipyridinones and quinoline N-oxides catalyzed by a rhodium complex allowed to incorporate indole rings
into aza-heteroaromatic compounds. These new transformations displayed complete regioselectivity for the C-6 position of
bipyridinones and the C-8 position of quinoline N-oxides and tolerated a broad range of functionalities, such as halogens, ethers, or
trifluoromethyl groups.
Introduction
Nitrogen-containing heteroaromatic compounds have valuable
properties in medicinal chemistry, pharmacology and func-
tional materials. Among those, pyridinone, sometimes called
pyridone, is a key structural motif of well-known active com-
pounds and natural products (Figure 1) [1]. For example, the
2-pyridinone ring is present in milrinone (1), used to treat heart
failure, while a 4-pyridinone is part of mimosine (2), an alka-
loid isolated from Mimosa pudica. A benzene-fused pyridinone
– a quinolone – can be found in brexpiprazole (3), a drug used
against schizophrenia. In addition, the indole core is also omni-
present in bioactive compounds [2]. It can be directly bound to
other heterocycles, such as a dihydropyrazidinone in hamacan-
thine A (4) (Figure 1) [3]. Due to their occurrence in biological-
ly active compounds, it is therefore attractive to develop new
methods to functionalize pyridinones. The introduction of
further heterocyclic rings, such as indoles, is particularly attrac-
tive.
Most of the methods for indolylpyridinone synthesis involve a
condensation cascade process to generate the pyridinone ring
[4-6]. These methods usually require an electron-withdrawing
group (nitrile, nitro, carbonyl), which ends up on the pyridi-
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Figure 1: Bioactive compounds with pyridinone, quinolone and indole cores.
Scheme 1: C–H functionalization of pyridinones and quinoline N-oxides.
none ring. As alternative, a Suzuki–Miyaura coupling between
3-halogenoindoles and (2-methoxypyridyl)boronic acids fol-
lowed by a deprotection of the methoxy group [7,8] or transi-
tion-metal-catalyzed annulation methods [9] have also been re-
ported.
In contrast, several procedures have been described for the
modification of pyridinones to introduce other substituents,
especially based on highly efficient C–H functionalization
methods [10]. Very recently, several research groups have
selectively functionalized the C-6 C–H bond by using a
2-pyridyl directing group on the nitrogen and a transition metal
catalyst (reaction 1, Scheme 1A) [11-19]. In particular, Li and
co-workers have used ethynylbenziodoxolone (EBX) hyperva-
lent iodine reagents to achieve a regiodivergent alkynylation of
the pyridinone core employing either a gold(I) or a rhodium(III)
catalyst for C-5 and C-6 functionalization, respectively [13].
Hypervalent iodine reagents in general [20], and benziodoxole
derivatives in particular [21], have found broad application in
synthetic chemistry. Aryl iodonium salts have been used suc-
cessfully in transition-metal-catalyzed transformations [22], but
only one application of indole iodonium salts in copper cataly-
sis by You and co-workers had been reported until 2017 [23]. In
this context, indole-based benziodoxole hypervalent iodine
reagents, recently introduced by Yoshikai's and our group [24-
27], appeared ideal partners to develop a new C–H heteroaryla-
tion of pyridinones.
Herein, we report the selective C–H heteroarylation of the C-6
position of bipyridinones by a rhodium-catalyzed reaction with
indoleBX (reaction 2, Scheme 1A). In addition, we demon-
strate that the mild conditions developed allow the heteroaryla-
tion of the C-8 position of quinoline N-oxides, whereas forma-
tion of the quinolinone had been observed in our previous work
(Scheme 1B). The obtained products combine up to three
classes of privileged heterocycles in medicinal chemistry in a
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Table 1: Optimization of the C–H heteroarylationa,b.
Entry Changes from conditions Yield (%)
1 [RhCp*Cl2]2 (2.5 mol %),
AgSbF6 (0.10 equiv),
NaOPiv (0.10 equiv),
DCE, 12 h, 50 °C
no reaction
2 – 86
3 without Zn(OTf)2 no reaction
4 without AgSbF6 60
5 under air atmosphere 80
6 60 °C 48
7 1 mol % of [RhCp*Cl2]2 75
8 1-methylindole (8) no reaction
9 3-iodo-1-methylindole (9) 0c
10 iodonium salt 10 0c
aReactions conditions: 5 (0.20 mmol), 6 (0.20 mmol), [RhCp*Cl2]2 (3.7 mg, 6.0 µmol, 3 mol %), AgSbF6 (10.3 mg, 30.0 µmol, 0.15 equiv), Zn(OTf)2
(10.9 mg, 30.0 µmol, 0.15 equiv), methanol (2.0 mL) at 80 °C for 12 h. bIsolated yield after preparative TLC. cDecomposition.
single compound, and are therefore expected to be highly use-
ful building blocks in the search for new bioactive compounds.
Results and Discussion
We started the studies on C–H indolation with the optimization
of the reactions conditions (Table 1) for the coupling of [1,2'-
bipyridin]-2-one (5a) with Me-indoleBX 6a, easily obtained
from commercially available 1-methylindole and 2-iodoben-
zoic acid [24]. While the reaction conditions previously de-
veloped in our group for the C–H functionalization of 2-phenyl-
pyridine [24] failed for the coupling of 5a with 6a (Table 1,
entry 1), we were pleased to see that addition of 0.15 equiv
Zn(OTf)2 allowed a full conversion to the desired product 7a in
86% yield (Table 1, entry 2). The Lewis acid is supposed to
weaken the O–I bond by coordination of the carboxy group in
6a. No base was required in this case. The reaction was com-
pletely selective for the C-6 position of the pyridinone ring.
Control experiments pointed out that both Lewis acid (Table 1,
entry 3) and AgSbF6 as additive (Table 1, entry 4) were neces-
sary for an efficient reaction. The transformation was tolerant to
air (Table 1, entry 5). However, more byproducts were ob-
served. Decreasing the temperature (Table 1, entry 6) or the
catalyst loading (Table 1, entry 7) resulted in lower yields.
Finally, three control experiments with 1-methylindole (8,
Table 1, entry 8), 3-iodo-1-methylindole (9, Table 1, entry 9)
and the poorly stable (1H-indol-3-yl)(phenyl)iodonium tetra-
fluoroborate [23] (10, Table 1, entry 10) did not lead to the for-
mation of 7a, highlighting the unique reactivity of the benzio-
doxolone hypervalent iodine reagent.
The scope and limitations of the reaction were then studied
(Scheme 2). The diversification of the directing group was ex-
amined first. The unsubstituted pyridine group led to the forma-
tion of product 7a in 86% yield. The electron-rich 5-methoxy-
pyridine and the electron-poor 5-trifluoromethylpyridine
directing groups gave products 7b and 7c in 82% and 72%
yield, respectively. When a nitro group was present on the pyri-
dine (5d), the product was not observed, probably due to a
weaker coordination of the nitrogen on the pyridine. Pyrimi-
dine could not be used as directing group (5e), confirming what
has already been reported by others authors [13]. Quinoline 7f
was obtained in 79% yield. Concerning the pyridinone core,
both an electron-donating methyl group and electron-with-
drawing trifluoromethyl and fluoro groups (7g–i) were well
tolerated in the C-3 position. However, the strong electron-with-
drawing CF3 group resulted in a lower 65% yield (7h). This ob-
servation is also true for the C-4 position. Indeed, products 7j–l
were synthesized in 78% yield for a methyl, 66% yield for a tri-
fluoromethyl and 84% yield for a benzyloxy substituent. As
previously reported [13], 5-substituted pyridinone 5m could not
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Scheme 2: Scope and limitations of the Rh-catalyzed C–H activation of [1,2'-bipyridin]-2-one.
be functionalized. Isoquinolone 7n was prepared in 82% yield.
The methodology could also be applied to 4-pyridone in a mod-
erate 57% yield for product 7o. Unfortunately, pyrazin-2-one 5p
could not be functionalized. Modification of the hypervalent
iodine reagent was then investigated with three selected com-
pounds only. A bromo substituent on the benzene ring was well
tolerated (7q). The coupling could be also performed with N–H
unprotected indoleBX reagents to afford products 7r and 7s in
84% and 77% yield, respectively.
We also applied these conditions to different quinoline N-oxides
(Scheme 3). This class of substrates had also been used for C–H
alkynylation using EBX reagents [28]. During our previous
work, we had attempted the C8-heteroarylation of quinoline
N-oxide with Me-indoleBX 6a. However, the transformation re-
quired a temperature of 100 °C, leading to the formation of the
corresponding isoquinolone in only 38% yield [24]. By employ-
ing the milder conditions developed for pyridinones, we were
pleased to see that the N-oxide group could be preserved and
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Scheme 3: Scope of the Rh-catalyzed peri C–H activation of quinoline N-oxides.
Scheme 4: Product modifications.
product 12a was obtained in 60% yield. A methyl substitution
in C-2 position gave the product 12b in 66% yield. In C-6 posi-
tion both a methoxy and a phenyl group were well tolerated
giving 57% and 73% yield of products 12c and 12d.
The pyridine directing group could be cleaved by alkylation of
the pyridine nitrogen using methyl triflate followed by reduc-
tion with sodium cyanoborohydride to deliver the N–H unpro-
tected pyridinone 13 in 74% yield (Scheme 4) [29]. A rear-
rangement of the N-oxide furnished the corresponding
isoquinolone 14 in 62% yield.
Conclusion
In summary, we have developed the C-6 selective C–H
heteroarylation of pyridin-2-ones using indoleBXs as coupling
partners, [RhCp*Cl2]2 as catalyst, AgSbF6 as co-catalyst and
Zn(OTf)2 as Lewis acid. The reaction could also be applied to
functionalize one pyridin-4-one in C-6 position, one isoquinoli-
none in C-3 position and quinoline N-oxides in C-8 position.
After cleavage of the directing group or rearrangement of the
N-oxide function, we were able to access 6-(indol-3-yl)pyridi-
none and 8-(indol-3-yl)quinolone. The developed transformat-
ions give access to important heterocyclic building blocks for
synthetic and medicinal chemistry and set the stages for the de-
velopment of other C–H heteroarylation processes based on
indoleBX reagents.
Experimental
General procedure for C–H heteroarylation
In a sealed tube, [RhCp*Cl2]2 (3.7 mg, 6.0 µmol, 3 mol %),
AgSbF6 (10.3 mg, 30.0 µmol, 0.15 equiv), Zn(OTf)2 (10.9 mg,
30.0 µmol, 0.15 equiv), the corresponding pyridinone or quino-
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line N-oxide (0.20 mmol, 1.00 equiv) and the corresponding
hypervalent iodine reagent (0.20 mmol, 1.00 equiv) were solu-
bilized in dry MeOH (2.0 mL, 0.1 M) under N2 atmosphere.
The mixture was stirred at 80 °C for 12 h. The mixture was then
diluted with DCM (5 mL) and quenched with a saturated
aqueous solution of NaHCO3 (5 mL). The two layers were sep-
arated and the aqueous layer was extracted twice with DCM
(5 mL). The organic layers were combined, dried over magne-
sium sulfate dehydrate, filtered and concentrated under reduced
pressure. The crude residue was purified by preparative TLC
using DCM/MeOH to afford the pure desired compound.
Supporting Information
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1. General methods 
 
All reagents and solvents were purchased from commercial sources ABCR, Acros, Sigma Aldrich, Fluka, 
VWR, Aplichem or Merck and used as such unless stated otherwise. Chromatographic purification was 
performed as flash chromatography using Macherey-Nagel silica 40-63, 60 Å. TLC was performed on 
Merck silica gel 60 F254 TLC glass plates and visualized with UV light, permanganate stain or 
phosphomolybdic acid stain. Melting points were measured on a calibrated Büchi B-540 melting point 
apparatus using open glass capillaries. 1H-NMR spectra were recorded on a Bruker DPX-400 400 MHz 
spectrometer in CDCl3, CD2Cl2 or DMSO-d6; all signals are reported in ppm with the internal chloroform 
signal at 7.26 ppm, the internal CD2Cl2 signal at 5.32 ppm or the internal DMSO signal at 2.50 ppm as 
standard. The data is being reported as (s = singlet d = doublet t = triplet q = quadruplet quint = quintet m = 
multiplet or unresolved bs = broad signal, coupling constant(s) in Hz, integration, interpretation). 19F-NMR 
spectra were recorded on a Bruker DPX-400 376 MHz spectrometer in CDCl3. 
13C-NMR spectra were 
recorded with 1H-decoupling on a Bruker DPX-400 101 MHz spectrometer in CDCl3, CD2Cl2 or DMSO-
d6; all signals are reported in ppm with the internal chloroform signal at 77.2 ppm, the internal CD2Cl2 
signal at 53.8 ppm or the internal DMSO signal at 39.5 ppm as standard. Infrared spectra were recorded on 
a JASCO FT-IR B4100 with an ATR device and a ZnSe prisma and are reported as cm-1 (w = weak, m = 
medium, s = strong, br = broad). High resolution mass spectrometric measurements were performed by the 
mass spectrometry service of ISIC at the EPFL on a MICROMASS (ESI) Q-TOF Ultima API. 
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2. Syntheses of starting materials 
 
2. 1. General procedure A for the synthesis of pyridinones 
 
 
 
Following a reported procedure,1 copper iodide (5 mol %), potassium phosphate tribasic (2.00 equiv), the 
corresponding 2-hydroxypyridine (1.00 equiv) and the corresponding 2-bromopyridine (2.00 equiv) were 
suspended in toluene [0.4 M] under N2. N,N’-dimethylethylenediamine (0.10 equiv) was added and the 
resulting mixture was stirred 20 h at 120 °C. The resulting mixture was allowed to cool to rt and then 
quenched with water. A small amount of N,N’-dimethylethylenediamine was added to dissolve the residual 
copper salts into the aqueous phase. The layers were separated and the aqueous layer was extracted three 
times with EtOAc (20 mL). The organic layers were combined, dried over MgSO4 and concentrated under 
reduced pressure. A purification by flash chromatography (eluent DCM/EtOAc 1:1 with 4%vv of NEt3) 
affordeded the desired product. 
 
2H-[1,2'-Bipyridin]-2-one (5a) 
 
Following general procedure A and starting from commercially available 2-hydroxypyridine 
(1.43 g, 15.0 mmol) and 2-bromopyridine (2.86 mL, 30.0 mmol), 5a (2.46 g, 14.3 mmol, 95%) 
(CAS number 3480-65-7) was obtained as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.56 (d, J = 4.7 Hz, 1H, HAr), 7.94 (d, J = 8.2 Hz, 1H, HAr), 
7.85 (ddd, J = 13.9, 7.4, 4.0 Hz, 2H, HAr), 7.38 (ddd, J = 8.9, 6.5, 2.0 Hz, 1H, HAr), 7.33-7.29 
(m, 1H, HAr), 6.64 (d, J = 9.2 Hz, 1H, HAr), 6.29 (t, J = 6.8 Hz, 1H, HAr). 
13C NMR (101 MHz, CDCl3) δ 162.3, 152.0, 149.0, 140.3, 137.9, 136.2, 123.3, 122.2, 121.6, 
106.4. Spectra data matched with the values reported in literature.2 
HRMS calculated for C10H8N2NaO
+ [M+Na]+ 195.0529; found 195.0535. 
 
5’-Methoxy-2H-[1,2'-bipyridin]-2-one (5b) 
 
Following general procedure A and starting from commercially available 2-hydroxypyridine 
(143 mg, 1.50 mmol) and 2-bromo-5-methoxypyridine (564 mg, 3.00 mmol), 5b (231 mg, 
1.14 mmol, 76%) (CAS number 10201-69-1) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.19 (d, J = 3.0 Hz, 1H, HAr), 7.80 (d, J = 8.9 Hz, 1H, HAr), 
7.76 (dd, J = 7.0, 1.9 Hz, 1H, HAr), 7.40-7.29 (m, 2H, HAr), 6.61 (d, J = 9.2 Hz, 1H, HAr), 6.26 
(td, J = 6.9, 1.2 Hz, 1H, HAr), 3.88 (s, 3H, OCH3). 
13C NMR (101 MHz, CDCl3) δ 162.4, 155.4, 145.0, 140.1, 136.5, 135.8, 122.4, 122.0, 121.9, 
106.2, 56.1. 
HRMS calculated for C11H11N2O2
+ [M+H]+ 203.0815; Found 203.0810. 
  
                                                   
1 Odani, R.; Hirano, K.; Satoh, T.; Miura, M. Angew. Chem. Int. Ed. 2014, 53, 10784–10788. 
2 Londregan, A. T.; Jennings, S.; Wei, L. Org. Lett. 2011, 13, 1840–1843. 
3 Pyridones 5b-d, 5e-m and 5p are known compounds, however no characterization has been reported. See Ref 1. 
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5’-(Trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (5c) 
 
Following general procedure A and starting from commercially available 2-hydroxypyridine 
(143 mg, 1.50 mmol) and 2-bromo-5-(trifluoromethyl)pyridine (678 mg, 3.00 mmol), 5c (245 
mg, 1.02 mmol, 68%) (CAS number 1845694-34-9) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.81 (s, 1H, HAr), 8.21 (d, J = 8.6 Hz, 1H, HAr), 8.05 (dd, J = 
8.6, 2.2 Hz, 1H, HAr), 7.96 (dd, J = 7.2, 1.5 Hz, 1H, HAr), 7.40 (ddd, J = 8.7, 6.5, 2.1 Hz, 1H, 
HAr), 6.64 (d, J = 9.3 Hz, 1H, HAr), 6.32 (td, J = 7.2, 1.3 Hz, 1H, HAr). 
19F NMR (376 MHz, CDCl3) δ -62.3. 
13C NMR (101 MHz, CDCl3) δ 162.2, 154.3, 146.0 (q, J = 4.2 Hz), 140.7, 135.3, 135.2 (q, J = 
3.3 Hz), 125.9 (q, J = 33.5 Hz), 123.2 (q, J = 272.3 Hz), 122.5, 121.2, 106.9. 
HRMS calculated for C11H8F3N2O
+ [M+H]+ 241.0583; Found 241.0581. 
 
5’-Nitro-2H-[1,2'-bipyridin]-2-one (5d) 
 
Following general procedure A and starting from commercially available 2-hydroxypyridine 
(143 mg, 1.50 mmol) and 2-bromo-5-nitropyridine (609 mg, 3.00 mmol), 5d (189 mg, 0.87 
mmol, 58%) (CAS number 10201-88-4) was obtained as yellow solid.3 
1H NMR (400 MHz, CDCl3) δ 9.38 (d, J = 2.6 Hz, 1H, HAr), 8.60 (dd, J = 9.0, 2.7 Hz, 1H, 
HAr), 8.40 (d, J = 9.0 Hz, 1H, HAr), 8.07 (dd, J = 7.3, 1.5 Hz, 1H, HAr), 7.43 (ddd, J = 8.7, 6.5, 
2.0 Hz, 1H, HAr), 6.67 (d, J = 9.3 Hz, 1H, HAr), 6.38-6.34 (m, 1H, HAr). 
13C NMR (101 MHz, CDCl3) δ 162.1, 155.3, 144.5, 142.9, 140.8, 134.9, 133.1, 122.6, 121.2, 
107.2. 
HRMS calculated for C10H8N3O3
+ [M+H]+ 218.0560; Found 218.0559. 
 
1-(Pyrimidin-2-yl)pyridin-4(1H)-one (5e) 
 
2-chloropyrimidine (172 mg, 1.50 mmol), 4-hydroxypyridine (285 mg, 3.00 mmol), K2CO3 
(415 mg, 3.00 mmol) were solubilized in water (2 mL) and heated at 90 °C for 30 min. After 
cooling at rt, the precipitate was filtered off and dried under vacuum to give 5e (159 mg, 
0.918 mmol, 61%) (CAS number 29049-26-1) as a white solid. 
1H NMR (400 MHz, CD2Cl2) δ 8.83 (d, J = 8.2 Hz, 2H), 8.73 (d, J = 4.8 Hz, 2H), 7.26 (t, J = 4.8 
Hz, 1H), 6.36 (d, J = 8.2 Hz, 2H). 
13C NMR (101 MHz, CD2Cl2) δ 180.5, 159.2, 156.0, 134.9, 119.1, 118.7. 
HRMS calculated for C9H8N3O+ [M+H]+ 174.0662; Found 174.0661. 
 
1-(Quinolin-2-yl)pyridin-2(1H)-one (5f) 
 
Following general procedure A and starting from commercially available 2-hydroxypyridine 
(152 mg, 1.60 mmol) and 2-bromoquinoline (666 mg, 3.20 mmol), 5f (342 mg, 1.54 mmol, 
96%) (CAS number 10168-48-6) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.27 (d, J = 8.7 Hz, 1H, HAr), 8.08 (d, J = 8.4 Hz, 1H, HAr), 
8.01 (t, J = 8.1 Hz, 2H, HAr), 7.89 (d, J = 8.1 Hz, 1H, HAr), 7.76 (t, J = 7.7 Hz, 1H, HAr), 
7.61 (t, J = 7.5 Hz, 1H, HAr), 7.44 (ddd, J = 8.9, 6.5, 1.9 Hz, 1H, HAr), 6.69 (d, J = 9.3 Hz, 
1H, HAr), 6.36 (t, J = 6.8 Hz, 1H, HAr). 
13C NMR (101 MHz, CDCl3) δ 162.7, 152.0, 147.3, 140.6, 137.9, 136.5, 130.2, 129.1, 127.7, 
127.7, 127.4, 122.4, 119.6, 106.7. 
HRMS calculated for C14H11N2O
+ [M+H]+ 223.0866; found 223.0872. 
 
3-Methyl-2H-[1,2'-bipyridin]-2-one (5g) 
 
S5 
 
Following general procedure A and starting from commercially available 2-hydroxy-3-
methylpyridine (458 mg, 4.20 mmol) and 2-bromopyridine (0.80 mL, 8.4 mmol), 5g (678 mg, 
3.64 mmol, 87%) (CAS number 1644063-32-0) was obtained as a colorless oil.3 
1H NMR (400 MHz, CDCl3) δ 8.59-8.54 (m, 1H, HAr), 7.95-7.91 (m, 1H, HAr), 7.85-7.79 (m, 1H, 
HAr), 7.73 (d, J = 7.1 Hz, 1H, HAr), 7.33-7.26 (m, 2H, HAr), 6.22 (t, J = 6.9 Hz, 1H, HAr), 2.19 (s, 3H, 
CH3). 
13C NMR (101 MHz, CDCl3) δ 162.7, 152.4, 148.9, 137.7, 137.3, 133.6, 130.9, 123.1, 121.7, 
106.1, 17.4. 
HRMS calculated for C11H11N2O
+ [M+H]+ 187.0866; found 187.0866. 
 
3-(Trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (5h) 
 
Following general procedure A and starting from commercially available 2-hydroxy-3-
(trifluoromethyl)-pyridine (326 mg, 2.00 mmol) and 2-bromopyridine (0.38 mL, 4.0 mmol), 
5h (252 mg, 1.05 mmol, 52%) (CAS number 1644063-33-1) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.56 (dd, J = 4.9, 1.7 Hz, 1H), 8.12 (dd, J = 7.1, 1.9 Hz, 1H), 
7.98 (d, J = 8.2 Hz, 1H), 7.88-7.79 (m, 2H), 7.35 (ddd, J = 7.4, 4.9, 0.9 Hz, 1H), 6.37 (t, J = 
7.0 Hz, 1H). 
19F NMR (376 MHz, CDCl3) δ -66.0. 
13C NMR (101 MHz, CDCl3) δ 158.1, 150.7, 149.0, 140.2, 139.7 (q, J = 4.9 Hz), 137.9, 123.8, 122.6 (q, J 
= 271.8 Hz), 121.8 (q, J = 30.9 Hz), 121.5, 104.4. 
HRMS calculated for C11H8F3N2O
+ [M+H]+ 241.0583; Found 241.0584. 
 
3-Fluoro-2H-[1,2'-bipyridin]-2-one (5i) 
 
Following general procedure A and starting from commercially available 3-fluro-2-
hydroxypyridine (226 mg, 2.00 mmol) and 2-bromopyridine (0.38 mL, 4.0 mmol), 5i (281 mg, 
1.48 mmol, 74%) (CAS number 1872255-08-7) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.56 (ddd, J = 4.9, 1.9, 0.8 Hz, 1H, HAr), 7.97 (dt, J = 8.2, 0.9 
Hz, 1H, HAr), 7.85 (ddd, J = 8.2, 7.5, 1.9 Hz, 1H, HAr), 7.74 (dt, J = 7.2, 1.7 Hz, 1H, HAr), 7.34 
(ddd, J = 7.4, 4.9, 1.0 Hz, 1H, HAr), 7.15 (ddd, J = 9.2, 7.4, 1.8 Hz, 1H, HAr), 6.22 (td, J = 7.3, 
4.5 Hz, 1H, HAr). 
19F NMR (376 MHz, CDCl3) δ -130.1. 
13C NMR (101 MHz, CDCl3) δ 156.2 (d, J = 26.5 Hz), 152.8 (d, J = 249.9 Hz), 151.1, 149.1, 138.1, 131.4 
(d, J = 5.3 Hz), 123.7, 121.4, 120.4 (d, J = 17.3 Hz), 104.1 (d, J = 5.9 Hz). 
HRMS calculated for C10H8FN2O
+ [M+H]+ 191.0615; Found 191.0618. 
 
4-Methyl-2H-[1,2'-bipyridin]-2-one (5j) 
 
Following general procedure A and starting from commercially available 2-hydroxy-4-
methylpyridine (458 mg, 4.20 mmol) and 2-bromopyridine (0.80 mL, 8.4 mmol), 5j (764 mg, 
4.10 mmol, 98%) (CAS number 1644063-34-2) was obtained as an off-white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 4.9 Hz, 1H, HAr), 7.95 (d, J = 8.2 Hz, 1H, HAr), 
7.84-7.76 (m, 2H, HAr), 7.29 (ddd, J = 7.3, 4.9, 0.9 Hz, 1H, HAr), 6.44 (s, 1H, HAr), 6.14 (dd, J 
= 7.2, 1.8 Hz, 1H, HAr), 2.22 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 162.2, 152.1, 152.0, 148.9, 137.8, 135.0, 123.1, 121.5, 120.2, 
109.2, 21.5. 
HRMS calculated for C11H11N2O
+ [M+H]+ 187.0866; found 187.0866. 
 
4-(Trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (5k) 
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Following general procedure A and starting from commercially available 2-hydroxy-3-
(trifluoromethyl)-pyridine (245 mg, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 
5k (203 mg, 0.850 mmol, 57%) (CAS number 1644063-35-3) was obtained as a pale yellow 
solid.3 
1H NMR (400 MHz, CDCl3) δ 8.57 (ddd, J = 4.9, 1.8, 0.8 Hz, 1H, HAr), 8.06 (d, J = 7.4 Hz, 
1H, HAr), 7.95 (dt, J = 8.2, 0.9 Hz, 1H, HAr), 7.85 (ddd, J = 8.2, 7.5, 1.9 Hz, 1H, HAr), 7.35 
(ddd, J = 7.4, 4.9, 1.0 Hz, 1H, HAr), 6.93-6.91 (m, 1H, HAr), 6.41 (dd, J = 7.4, 2.0 Hz, 1H, HAr). 
19F NMR (376 MHz, CDCl3) δ -67.0. 
13C NMR (101 MHz, CDCl3) δ 161.1, 151.0, 149.2, 141.7 (q, J = 34.0 Hz), 138.1, 138.0, 123.8, 
122.1 (q, J = 274.0 Hz), 121.2, 119.9 (q, J = 4.4 Hz), 101.6 (q, J = 2.4 Hz). 
HRMS calculated for C11H8F3N2O+ [M+H]+ 241.0583; Found 241.0582. 
 
4-(Benzyloxy)-2H-[1,2'-bipyridin]-2-one (5l) 
 
Following general procedure A and starting from commercially available 4-benzyloxy-2-
hydroxypyridine (302 g, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 5l (113 mg, 
0.410 mmol, 27%) (CAS number 1644063-36-4) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 3.9 Hz, 1H, HAr), 7.94 (d, J = 8.2 Hz, 1H, HAr), 
7.86-7.78 (m, 2H, HAr), 7.403-7.33 (m, 5H, HAr), 7.30-7.27 (m, 1H, HAr), 6.11 (dd, J = 7.8, 2.6 
Hz, 1H, HAr), 6.03 (d, J = 2.5 Hz, 1H, HAr), 5.05 (s, 2H, OCH2). 
13C NMR (101 MHz, CDCl3) δ 167.7, 163.7, 151.8, 148.9, 137.8, 136.2, 135.3, 128.9 (2C), 
128.7, 127.9 (2C), 122.9, 121.5, 102.2, 98.6, 70.5. 
HRMS calculated for C17H14N2NaO2
+ [M+Na]+ 301.0953; Found 301.0948. 
 
5-Methyl-2H-[1,2'-bipyridin]-2-one (5m) 
 
Following general procedure A and starting from commercially available 2-hydroxy-4-
methylpyridine (458 mg, 4.20 mmol) and 2-bromopyridine (0.80 mL, 8.4 mmol), 5m (691 
mg, 3.71 mmol, 88%) (CAS number 53427-88-6) was obtained as a white solid.3 
1H NMR (400 MHz, CDCl3) δ 8.55 (d, J = 3.9 Hz, 1H, HAr), 7.93 (d, J = 8.1 Hz, 1H, HAr), 
7.85-7.78 (m, 1H, HAr), 7.64 (s, 1H, HAr), 7.32-7.22 (m, 2H, HAr), 6.58 (d, J = 9.3 Hz, 1H, 
HAr), 2.12 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 161.6, 152.1, 148.9, 143.1, 137.7, 133.2, 123.0, 121.7, 121.6, 
115.3, 17.3. 
HRMS calculated for C11H11N2O
+ [M+H]+ 187.0866; found 187.0867. 
 
2-(Pyridin-2-yl)isoquinolin-1(2H)-one (5n) 
 
Following general procedure A and starting from commercially available isoquinolin-1(2H)-
one (218 mg, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 5n (276 mg, 1.24 mmol, 
83%) (CAS number 1532-89-4) was obtained as a white solid. 
1H NMR (400 MHz, CDCl3) δ 8.59 (dd, J = 4.8, 1.7 Hz, 1H), 8.49 (d, J = 8.0 Hz, 1H), 8.01 
(d, J = 8.2 Hz, 1H), 7.86 (td, J = 7.8, 1.9 Hz, 1H), 7.78 (d, J = 7.6 Hz, 1H), 7.69 (td, J = 8.2, 
7.8, 1.3 Hz, 1H), 7.58-7.49 (m, 2H), 7.31 (ddd, J = 7.3, 4.9, 0.9 Hz, 1H), 6.63 (d, J = 7.6 Hz, 
1H). 
13C NMR (101 MHz, CDCl3) δ 162.1, 152.4, 148.9, 137.7, 137.2, 133.0, 130.1, 128.5, 127.2, 
126.7, 126.1, 122.7, 121.7, 106.9. Spectra data matched with the values reported in literature.2 
HRMS calculated for C14H10N2NaO+ [M+Na]+ 245.0685; Found 245.0694. 
 
4H-[1,2'-bipyridin]-4-one (5o) 
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Following general procedure A and starting from commercially available 4-hydroxypyridine (143 
mg, 1.50 mmol) and 2-bromopyridine (0.29 mL, 3.0 mmol), 5o (181 mg, 1.05 mmol, 70%) (CAS 
number 76520-27-9) was obtained as a yellow solid. 
1H NMR (400 MHz, CDCl3) δ 8.49 (d, J = 4.8 Hz, 1H, HAr), 8.18 (d, J = 8.0 Hz, 2H, HAr), 7.89 
(ddd, J  = 15.7, 8.2, 1.9 Hz, 1H, HAr), 7.38 (d, J = 8.3 Hz, 1H, HAr), 7.30 (dd, J = 7.4, 4.8 Hz, 1H, 
HAr), 6.45 (d, J = 8.0 Hz, 2H, HAr). 
13C NMR (101 MHz, CDCl3) δ 180.0, 152.1, 149.2, 139.7, 136.1 (2C), 122.6, 118.9 (2C), 113.0. 
Spectra data matched with the values reported in literature.2 
HRMS calculated for C10H9N2O+ [M+H]+ 173.0709; Found 173.0713. 
 
1-(Pyridin-2-yl)pyrazin-2(1H)-one (5p) 
 
Following general procedure A and starting from commercially available 2-hydroxy-4-
methylpyridine (192 mg, 2.00 mmol) and 2-bromopyridine (0.38 mL, 4.0 mmol), 5p (335 mg, 
1.93 mmol, 97%) was obtained as a white solid. mp 124-126 °C. Rf 0.80 (DCM/MeOH 19:1).3 
1H NMR (400 MHz, CDCl3) δ 8.58 (dd, J = 4.9, 1.0 Hz, 1H, HAr), 8.25 (d, J = 0.9 Hz, 1H, 
HAr), 8.16 (d, J = 8.2 Hz, 1H, HAr), 7.94 (dd, J = 4.7, 1.0 Hz, 1H, HAr), 7.87 (td, J = 7.9, 1.8 
Hz, 1H, HAr), 7.42 (d, J = 4.7 Hz, 1H, HAr), 7.36 (ddd, J = 7.4, 4.9, 0.6 Hz, 1H, HAr). 
13C NMR (101 MHz, CDCl3) δ 155.5, 151.5, 149.9, 149.1, 138.3, 125.3, 123.9, 123.9, 120.4. 
IR 2994 (w), 1679 (s), 1587 (s), 1569 (s), 1502 (s), 1470 (m), 1443 (s), 1287 (s), 1264 (s), 1250 (s), 1216 
(s), 1156 (m), 1034 (m), 1020 (m), 995 (m), 851 (m), 798 (s), 782 (s), 736 (s). 
HRMS calculated for C9H8N3O
+ [M+H]+ 174.0662; found 174.0662. 
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2.2. General procedure B for the synthesis of N-alkylindoles 
 
 
 
Sodium hydride (60% in mineral oil, 1.10 equiv) was suspended in DMF [0.6 M]. N-H-indole (1.00 equiv) 
was solubilized in DMF [1.0 M] and added to the suspension at 0 °C. The mixture was stirred at rt for 30 
min. Bromoalkyl or TMSCl (1.50 equiv) was diluted in DMF [3.0 M] and added to the solution at 0 °C. The 
mixture was stirred at rt for 1 hour. The solution was quenched with water (20 mL) and extracted three times 
with EtOAc (10 mL). The organic layers were combined, dried over MgSO4 and concentrated under reduced 
pressure. The liquid was filtered through a 5 cm pad of silica with 100% pentane or Et2O to afforded the 
title compound. 
 
5-Bromo-1-methyl-1H-indole (15b) 
 
Following general procedure B and starting from commercially available 5-bromoindole 
(0.59 mg, 3.0 mmol), 15b (630 mg, 3.00 mmol, quantitative yield) (CAS number 10075-
52-2) was obtained as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 1.6 Hz, 1H, HAr), 7.30 (dd, J = 8.7, 1.8 Hz, 1H, 
HAr), 7.19 (d, J = 8.7 Hz, 1H, HAr), 7.05 (d, J = 3.1 Hz, 1H, HAr), 6.43 (d, J = 3.1 Hz, 1H, 
HAr), 3.78 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 135.5, 130.2, 130.1, 124.4, 123.4, 112.8, 110.8, 100.6, 33.1. Spectra data 
matched with the values reported in literature.4 
 
1-(Tert-butyldimethylsilyl)-1H-indole (15c) 
 
Following general procedure B and starting from commercially available indole (2.34 g, 20.0 
mmol), 15c (4.63 g, 20.0 mmol, quantitative yield) (CAS number 40899-73-8) was obtained 
as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 7.2 Hz, 1H, HAr), 7.44 (d, J = 7.7 Hz, 1H, HAr), 
7.10 (d, J = 3.2 Hz, 1H, HAr), 7.09-6.99 (m, 2H, HAr), 6.54 (d, J = 2.7 Hz, 1H, HAr), 0.85 (s, 
9H, C(CH3)3), 0.52 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 141.1, 131.5, 131.1, 121.5, 120.8, 119.9, 114.0, 104.9, 26.5, 
19.7, -3.8. Spectra data matched with the values reported in literature.5 
 
6-Bromo-1-(tert-butyldimethylsilyl)-1H-indole (15d) 
 
Following general procedure B and starting from commercially available indole (2.34 g, 
20.0 mmol), Xd (4.63 g, 20.0 mmol, quantitative yield) (CAS number 40899-73-8) was 
obtained as a pale yellow solid. 
1H NMR (400 MHz, CDCl3) δ 7.64 (s, 1H, HAr), 7.48 (d, J = 8.4 Hz, 1H, HAr), 7.21 (dd, 
J = 8.4, 1.7 Hz, 1H, HAr), 7.15 (d, J = 3.2 Hz, 1H, HAr), 6.58 (dd, J = 3.2, 0.8 Hz, 1H, 
HAr), 0.93 (s, 9H, C(CH3)3), 0.61 (s, 6H, Si(CH3)2). 
13C NMR (101 MHz, CDCl3) δ 142.1, 131.9, 130.4, 123.3, 121.9, 116.9, 115.2, 105.1, 
26.5, 19.7, -3.7. Spectra data matched with the values reported in literature.6 
 
  
                                                   
4 Greulich, T.W.; Daniliuc, C.J.; Studer, A. Org. Lett. 2015, 17, 254−257. 
5 Dhanak, D.; Reese, C. B. J. Chem. Soc., Perkin Trans. 1 1986, 2181–2186. 
6 Kawasaki, I.; Yamashita, M; Ohta, S. Chem. Pharm. Bull. 1996, 44, 1831–1839. 
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2.3. General procedure C for the synthesis of indoleBX reagents 
 
1-Acetoxy-1,2-benziodoxol-3-(1H)-one (18) 
 
 
Following a reported procedure7, sodium periodate (18.1 g, 85.0 mmol, 1.05 equiv) and 2-iodobenzoic acid 
(20.0 g, 81.0 mmol, 1.00 equiv) were suspended in 30% (v:v) aq. AcOH (160 mL). The mixture was 
vigorously stirred and refluxed for 4 h and allowed to cool to room temperature, while protecting it from 
light. After 1 h, the crude product was collected by filtration. The crystals were washed with ice water (3 x 
40 mL) followed by acetone (45 mL) and dried under reduced pressure in the dark to afforded 1-hydroxy-
1,2-benziodoxol-3-(1H)-one (20.8 g, 79.0 mmol, 98%) as a white solid. Following a reported procedure, 1-
hydroxy-1,2-benziodoxol-3-(1H)-one (20.8 g, 79.0 mmol, 1.00 equiv) was suspended in acetic anhydride 
(75.0 mL, 788 mmol, 10.0 equiv) and heated to reflux (140 °C) until complete dissolution (about 15 min). 
The resulting clears solution was slowly let to cool to room temperature and then cooled to 5 °C in the 
fridge. The white crystals were filtered, washed with pentane (3 x 30 mL) and dried under reduced pressure 
to afforded 1-acetoxy-1,2-benziodoxol-3-(1H)-one (22.3 g, 73.0 mmol, 92%) as a white solid. 
 
 
 
Following a slightly modified reported procedure,8 1-acetoxy-1,2- benziodoxol-3-(1H)-one (1.20 equiv), 
the corresponding azaheterocycle (1.00 equiv) and zinc (II) trifluoromethanesulfonate (0.20 equiv) were 
dissolved in DCM [0.05 M]. The reaction was stirred overnight at room temperature, directly purified by 
flash chromatography (eluent DCM/MeOH see ratio thereafter) and triturated in ACN to afforded the pure 
desired hypervalent iodine reagent. 
 
1-(3-1-Methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (6a) 
 
Following general procedure C, starting from commercially available 1-
methylindole (0.43 mL, 3.4 mmol) and 16, a purification by column chromatography 
(DCM/MeOH 19:1) affordeded the title compound 6a (0.79 g, 2.1 mmol, 61% yield) 
(CAS number 2130906-04-4) as an off-white solid. 
1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 7.5 Hz, 1H, HAr), 7.77 (s, 1H, CH-N), 
7.56-7.49 (m, 2H, HAr), 7.47-7.41 (m, 2H, HAr), 7.35-7.26 (m, 2H, HAr), 6.85 (d, J = 8.2 Hz, 1H, HAr), 4.02 
(s, 3H, NCH3). 
                                                   
7 Parsons, A. T.; Buchwald, S. L. Angew. Chem. Int. Ed. 2011, 50, 9120–9123. 
8 Caramenti, P.; Nicolai, S.; Waser, J. Chem. - Eur. J. 2017, 23, 14702–14706. 
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13C NMR (101 MHz, CDCl3) δ 167.0, 138.7, 137.7, 133.6, 133.4, 132.7, 130.7, 129.5, 125.4, 124.5, 122.8, 
120.1, 116.3, 110.9, 79.2, 34.1. Spectra data matched with the values reported in literature.7 
 
1-(3-5-Bromo-1-methyl-1H-indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (6b) 
 
Following general procedure C, starting from 15b (406 mg, 1.93 mmol) and 16, a 
purification by column chromatography (DCM/MeOH 19:1) affordeded the title 
compound 6b (470 mg, 1.03 mmol, 53% yield) as an off-white solid. 
1H NMR (400 MHz, CD2Cl2) δ 8.33 (d, J = 7.4 Hz, 1H, HAr), 7.70 (s, 1H, CH-N), 
7.63 (s, 1H, HAr), 7.57 (t, J = 7.3 Hz, 1H, HAr), 7.52 (dd, J = 8.8, 1.6 Hz, 1H, HAr), 
7.44 (d, J = 8.8 Hz, 1H, HAr), 7.34 (t, J = 7.1 Hz, 1H, HAr), 6.84 (d, J = 8.3 Hz, 1H, 
HAr), 3.96 (s, 3H, NCH3). 
13C NMR (101 MHz, CD2Cl2) δ 166.6, 139.9, 136.9, 133.9, 133.7, 132.5, 131.5, 131.0, 127.5, 125.7, 123.0, 
116.7, 116.2, 112.8, 79.5, 34.4. Spectra data matched with the values reported in literature.9 
 
1-(3-1H-Indole)-1H-1λ3 -benzo[b]iodo-3(2H)-one (6c) 
 
Following general procedure C but replacing Zn(OTf)2 by Sc(OTf)3, starting from 
15c (579 mg, 2.50 mmol) and 16, a purification by column chromatography 
(DCM/MeOH 5:1) affordeded the title compound 6c (527 mg, 1.45 mmol, 58% 
yield) as a pale beige solid. 
1H NMR (400 MHz, DMSO-d6) δ 12.36 (s, 1H, NH), 8.26 (s, 1H, CH-N), 8.12 (d, 
J = 7.3 Hz, 1H, HAr), 7.64 (d, J = 8.2 Hz, 1H, HAr), 7.56 (t, J = 7.3 Hz, 1H, HAr), 7.49 (d, J = 7.9 Hz, 1H, 
HAr), 7.41 (t, J = 7.6 Hz, 1H, HAr), 7.31 (t, J = 7.6 Hz, 1H, HAr), 7.20 (t, J = 7.5 Hz, 1H, HAr), 6.76 (d, J = 
8.2 Hz, 1H, HAr). 
13C NMR (101 MHz, DMSO-d6) δ 165.8, 136.5 (2C), 134.6, 133.1, 131.3, 130.1, 128.6, 126.2, 123.3, 
121.6, 119.2, 116.0, 112.9, 80.3. Spectra data matched with the values reported in literature.7 
 
1-(3-(6-Bromo-1H-indole))-1H-1λ3 -benzo[b]iodo-3(2H)-one (6d) 
 
Following general procedure C, but replacing Zn(OTf)2 by Sc(OTf)3, starting 
from 15d (528 mg, 1.70 mmol) and 16, a purification by column 
chromatography (DCM/MeOH 19:1) and washing with DCM affordeded the 
title compound 6d (563 mg, 1.27 mmol, 75% yield) as a white solid. mp 194-
196 °C. Rf 0.58 (DCM/MeOH 9:1). 
1H NMR (400 MHz, DMSO-d6) δ 12.46 (bs, 1H, NH), 8.27 (s, 1H, HAr), 8.12 (dd, J = 7.5, 1.5 Hz, 1H, 
HAr), 7.86 (d, J = 1.5 Hz, 1H, HAr), 7.57 (t, J = 7.3 Hz, 1H, HAr), 7.49 (d, J = 8.5 Hz, 1H, HAr), 7.42 (td, J = 
7.3, 1.5 Hz, 1H, HAr), 7.32 (dd, J = 8.5, 1.7 Hz, 1H, HAr), 6.74 (d, J = 8.1 Hz, 1H, HAr). 
13C NMR (101 MHz, DMSO-d6) δ 165.9, 137.5, 137.4, 134.4, 133.3, 131.4, 130.2, 127.7, 126.3, 124.4, 
121.2, 116.1, 116.0, 115.4, 80.9. 
IR νmax 2606 (br), 1593 (m), 1578 (m), 1549 (m), 1366 (s), 1265 (m), 887 (m), 828 (s), 794 (s), 736 (s). 
HRMS calculated for C15H10
79BrINO2
+ [M+H]+ 441.8934; found 441.8933.  
                                                   
9 Grenet, E.; Waser, J. Org. Lett. 2018, 20, 1473-1475. 
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3. General procedure D for the synthesis of 6-(indol-3-yl)-1,2'-bipyridin-2-ones 
 
 
 
In a sealed tube, [RhCp*Cl2]2 (3.7 mg, 6.0 µmol, 3 mol %), AgSbF6 (10.3 mg, 30.0 µmol, 0.15equiv), 
Zn(OTf)2 (10.9 mg, 30.0 µmol, 0.15 equiv), the corresponding pyridinone (0.20 mmol, 1.00 equiv) and 
the corresponding hypervalent iodine reagent (0.20 mmol, 1.00 equiv) were solubilized in dry MeOH 
(2.0 mL, 0.1 M) under N2. The mixture was stirred at 80 °C for 12 h. The suspension was diluted with 
DCM (5 mL) and quenched with a saturated aqueous solution of NaHCO3 (5 mL). The two layers were 
separated and the aqueous layer was extracted twice with DCM (5 mL). The organic layers were 
combined, dried over magnesium sulfate dehydrate, filtered and concentrated under reduced pressure. 
The crude residue was purified by preparative TLC using DCM/MeOH 19:1 as eluent to afforded the 
pure title compound. 
 
6-(1-Methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7a) 
 
Following General Procedure D, starting from 5a and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7a (51.9 mg, 
0.172 mmol, 86% yield) as a white solid. mp 231-233 °C. Rf 0.51 (DCM/MeOH 
19:1). 
1H NMR (400 MHz, CDCl3) δ 8.58 (ddd, J = 4.9, 1.8, 0.7 Hz, 1H, HAr), 7.71 (d, J 
= 8.0 Hz, 1H, HAr), 7.63 (td, J = 7.7, 1.9 Hz, 1H, HAr), 7.50 (dd, J = 9.2, 7.0 Hz, 
1H, HAr), 7.25-7.21 (m, 3H, HAr), 7.19-7.12 (m, 2H, HAr), 6.63 (dd, J = 9.2, 1.1 Hz, 1H, HAr), 6.50 (dd, J = 
7.0, 1.1 Hz, 1H, HAr), 6.47 (s, 1H, C2indoleH), 3.57 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 164.2, 153.2, 149.2, 143.2, 140.3, 138.4, 136.3, 129.9, 126.7, 124.2, 123.7, 
122.6, 120.6, 119.9, 118.7, 109.6, 109.5, 108.0, 33.0. 
IR νmax 3080 (w), 1660 (s), 1591 (s), 1580 (s), 1557 (s), 1437 (m), 1391 (m), 1237 (m), 1142 (m), 807 (s), 
786 (m), 750 (s). 
HRMS calculated for C19H16N3O
+ [M+H]+ 302.1288; Found 302.1291. 
 
5'-Methoxy-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7b) 
 
Following General Procedure D, starting from 5b and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7b (54.3 mg, 
0.164 mmol, 82% yield) as a yellow solid. mp 225-227 °C. Rf 0.51 (DCM/MeOH 
19:1). 
1H NMR (400 MHz, CDCl3) δ 8.13 (d, J = 2.6 Hz, 1H, HAr), 7.61 (d, J = 8.0 Hz, 
1H, HAr), 7.37 (dd, J = 9.2, 7.0 Hz, 1H, HAr), 7.14 (d, J = 3.8 Hz, 2H, HAr), 7.09-
7.00 (m, 2H, HAr), 6.95 (d, J = 8.7 Hz, 1H, HAr), 6.50 (dd, J = 9.2, 1.2 Hz, 1H, HAr), 
6.41 (s, 1H, C2indoleH), 6.37 (dd, J = 7.0, 1.2 Hz, 1H, HAr), 3.72 (s, 3H, OCH3), 3.50 
(s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 164.5, 155.5, 145.7, 143.6, 140.1, 136.3, 136.2, 130.0, 126.7, 124.2, 122.9, 
122.6, 120.6, 119.9, 118.5, 109.6, 109.6, 107.9, 56.0, 33.1. 
IR νmax 3080 (w), 1662 (s), 1582 (s), 1543 (s), 1473 (s), 1260 (s), 807 (s), 752 (s), 737 (s). 
HRMS calculated for C20H18N3O2
+ [M+H]+ 332.1394; Found 332.1392. 
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6-(1-Methyl-1H-indol-3-yl)-5'-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (7c) 
 
Following General Procedure D, starting from 5c and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7c (53.2 mg, 
0.144 mmol, 72% yield) as a yellow solid. mp > 300 °C. Rf 0.74 (DCM/MeOH 
19:1). 
1H NMR (400 MHz, CDCl3) δ 8.82 (s, 1H, HAr), 7.88 (d, J = 8.2 Hz, 1H, HAr), 7.66 
(d, J = 8.0 Hz, 1H, HAr), 7.54 (dd, J = 9.2, 7.0 Hz, 1H, HAr), 7.34 (d, J = 8.2 Hz, 
1H, HAr), 7.29-7.24 (m, 2H, HAr), 7.22-7.11 (m, 1H, HAr), 6.67 (d, J = 9.2 Hz, 1H, 
HAr), 6.54-6.49 (m, 2H, HAr + C2indoleH), 3.63 (s, 1H, NCH3). 
19F NMR (376 MHz, CDCl3) δ -62.3. 
13C NMR (101 MHz, CDCl3) δ 164.0, 156.1, 146.4 (q, J = 3.6 Hz), 142.9, 140.7, 136.4, 135.7 (q, J = 3.2 
Hz), 129.7, 126.6 (q, J = 33.5 Hz), 126.5, 124.4, 123.2 (q, J = 272.7 Hz), 122.9, 120.8, 119.7, 118.9, 109.8, 
109.3, 108.5, 33.1. 
IR νmax 1663 (m), 1583 (m), 1544 (m), 1326 (s), 1128 (s), 1081 (s), 1017 (s), 799 (s), 743 (s). 
HRMS calculated for C20H15F3N3O
+ [M+H]+ 370.1162; Found 370.1160. 
 
6-(1-Methyl-1H-indol-3-yl)-1-(quinolin-2-yl)pyridin-2(1H)-one (7f) 
 
Following General Procedure D, starting from 5f and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7f (55.4 mg, 
0.158 mmol, 79% yield) as a pale yellow solid. mp 231-233 °C. Rf 0.58 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.12 (d, J = 8.6 Hz, 1H, HAr), 8.08 (d, J = 8.6 Hz, 
1H, HAr), 7.80-7.71 (m, 3H, HAr), 7.59-7.52 (m, 2H, HAr), 7.23-7.13 (m, 4H, HAr), 
6.66 (dd, J = 9.2, 1.2 Hz, 1H, HAr), 6.55-6.52 (m, 2H, HAr + C2indoleH), 3.39 (s, 3H, 
NCH3). 
13C NMR (101 MHz, CDCl3) δ 164.3, 152.5, 147.1, 143.1, 140.4, 138.8, 136.2, 130.4, 130.1, 129.5, 127.8, 
127.7, 127.5, 126.9, 122.6, 121.6, 120.7, 119.8, 118.8, 109.6, 109.2, 108.1, 32.9. 
IR νmax 3062 (w), 1669 (s), 1586 (s), 1544 (s), 1504 (m), 1398 (m), 1236 (m), 815 (s), 803 (s), 768 (s), 745 
(s). 
HRMS calculated for C23H17N3NaO
+ [M+Na]+ 374.1264; found 374.1271. 
 
3-Methyl-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7g) 
 
Following General Procedure D, starting from 5g and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7g (50.5 mg, 
0.160 mmol, 80% yield) as a pale yellow solid. mp 228-230 °C. Rf 0.51 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.57 (dd, J = 4.9, 1.1 Hz, 1H, HAr), 7.70 (d, J = 
8.0 Hz, 1H, HAr), 7.61 (td, J = 7.7, 1.9 Hz, 1H, HAr), 7.38 (dd, J = 7.0, 1.1 Hz, 1H, 
HAr), 7.24-7.19 (m, 3H, HAr), 7.18-7.10 (m, 2H, HAr), 6.46 (s, 1H, C2indoleH), 6.43 
(d, J = 7.0 Hz, 1H, HAr), 3.57 (s, 3H, NCH3), 2.22 (d, J = 0.8 Hz, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 164.4, 153.6, 149.1, 140.2, 138.2, 137.5, 136.3, 129.6, 127.7, 126.8, 124.2, 
123.5, 122.5, 120.4, 119.9, 109.8, 109.5, 107.7, 32.9, 17.1. 
IR νmax 3087 (w), 2926 (w), 1650 (s), 1603 (m), 1556 (s), 1469 (m), 1243 (m), 1133 (m), 809 (m), 792 (s), 
746 (s). 
HRMS calculated for C20H18N3O
+ [M+H]+ 316.1444; Found 316.1448. 
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6-(1-Methyl-1H-indol-3-yl)-3-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (7h) 
 
Following General Procedure D, starting from 5h and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7h (48.0 mg, 
0.130 mmol, 65% yield) as an off-white solid. mp 265-267 °C. Rf 0.71 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CD2Cl2) δ 8.59 (d, J = 3.5 Hz, 1H, HAr), 7.89 (d, J = 7.5 
Hz, 1H, HAr), 7.73 (d, J = 7.3 Hz, 2H, HAr), 7.39-7.09 (m, 5H, HAr), 6.60 (d, J = 
7.5 Hz, 1H, HAr), 6.46 (s, 1H, C2indoleH), 3.57 (s, 3H, NCH3). 
19F NMR (376 MHz, CDCl3) δ -63.6. 
13C NMR (101 MHz, CD2Cl2) δ 160.1, 152.6, 149.7, 148.6, 139.8 (q, J = 4.8 Hz), 138.9, 136.8, 131.2, 
126.6, 124.6, 124.4, 123.7 (q, J = 270.8 Hz), 123.2, 121.4, 119.8, 117.0 (q, J = 30.7 Hz), 110.3, 108.7, 105.9, 
33.4. 
IR νmax 3105 (w), 1672 (m), 1555 (s), 1416 (m), 1318 (s), 1142 (s), 1117 (s), 1104 (s), 1057 (s), 1038 (s), 
739 (s). 
HRMS calculated for C20H14F3N3NaO
+ [M+Na]+ 392.0981; Found 392.0984. 
 
3-Fluoro-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7i) 
 
Following General Procedure D, starting from 5i and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7i (47.9 mg, 
0.150 mmol, 75% yield) as an off-white solid. mp 204-206 °C. Rf 0.58 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.56 (dd, J = 4.9, 1.2 Hz, 1H, HAr), 7.67-7.62 (m, 
2H, HAr), 7.30-7.24 (m, 2H, HAr), 7.24-7.21 (m, 2H, HAr), 7.18-7.11 (m, 2H, HAr), 
6.50 (s, 1H, C2indoleH), 6.38 (dd, J = 7.8, 4.4 Hz, 1H, HAr), 3.59 (s, 3H, NCH3). 
19F NMR (376 MHz, CDCl3) δ -133.9. 
13C NMR (101 MHz, CDCl3) δ 157.5 (d, J = 26.0 Hz), 152.1 (d, J = 1.3 Hz), 151.0 (d, J = 248.5 Hz), 
149.3, 138.7 (d, J = 5.4 Hz), 138.5, 136.2, 129.7, 126.6, 124.0, 123.9, 122.6, 120.9 (d, J = 16.5 Hz), 120.6, 
119.6, 109.6, 108.9, 105.5 (d, J = 5.1 Hz), 33.0. 
IR νmax 3056 (w), 1673 (s), 1617 (s), 1570 (m), 1278 (s), 1239 (s), 1223 (m), 1137 (m), 819 (m), 784 (m), 
753 (s), 745 (s). 
HRMS calculated for C19H15FN3O
+ [M+H]+ 320.1194; Found 320.1192. 
 
4-Methyl-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7j) 
 
Following General Procedure D, starting from 5j and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7j (49.2 mg, 
0.156 mmol, 78% yield) as an off-white solid. mp 186-188 °C. Rf 0.41 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 4.6, 1.4 Hz, 1H, HAr), 7.70 (d, J = 8.0 
Hz, 1H, HAr), 7.60 (td, J = 7.7, 1.9 Hz, 1H, HAr), 7.24-7.09 (m, 5H, HAr), 6.49 (s, 
1H, C2indoleH), 6.44 (s, 1H, C(O)CH), 6.34 (d, J = 1.6 Hz, 1H), 3.57 (s, 3H, NCH3), 
2.28 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 164.2, 153.2, 151.7, 149.1, 141.8, 138.2, 136.3, 129.9, 126.6, 124.3, 123.5, 
122.5, 120.5, 119.8, 117.2, 110.6, 109.6, 109.5, 33.0, 21.7. 
IR νmax 2970 (m), 2902 (m), 1657 (s), 1599 (s), 1588 (s), 1549 (s), 1470 (s), 1435 (m), 1396 (s), 1339 (m), 
1261 (m), 1239 (m), 1070 (s), 1051 (s), 1011 (s), 826 (m), 786 (m), 732 (s). 
HRMS calculated for C20H18N3O
+ [M+H]+ 316.1444; Found 316.1446. 
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6-(1-Methyl-1H-indol-3-yl)-4-(trifluoromethyl)-2H-[1,2'-bipyridin]-2-one (7k) 
 
Following General Procedure D, starting from 5k and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7k (48.7 mg, 
0.132 mmol, 66% yield) as a pale yellow solid. mp 200-202 °C. Rf 0.65 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.60 (d, J = 3.7 Hz, 1H, HAr), 7.68 (ddd, J = 12.2, 
6.4, 2.3 Hz, 2H, HAr), 7.33-7.13 (m, 5H, HAr), 6.88 (s, 1H, C(O)CH), 6.63 (d, J = 
1.5 Hz, 1H, HAr), 6.51 (s, 1H, C2indoleH), 3.59 (s, 3H, NCH3). 
19F NMR (376 MHz, CDCl3) δ -66.8. 
13C NMR (101 MHz, CDCl3) δ 163.3, 152.5, 149.5, 145.4, 141.8 (q, J = 33.5 Hz), 138.7, 136.4, 130.4, 
126.3, 124.2, 124.0, 123.1, 122.6 (q, J = 274.2 Hz), 121.2, 119.6, 115.7 (q, J = 4.0 Hz), 109.8, 108.8, 102.7 
(q, J = 2.1 Hz), 33.1. 
IR νmax 3099 (w), 3062 (w), 2926 (w), 1675 (m), 1610 (m), 1552 (s), 1282 (s), 1170 (s), 1133 (s), 1079 (m), 
1006 (m), 932 (m), 857 (s), 734 (s). 
HRMS calculated for C20H14F3N3NaO
+ [M+Na]+ 392.0981; Found 392.0990. 
 
4-(Benzyloxy)-6-(1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7l) 
 
Following General Procedure D, starting from 5l and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7l (68.4 mg, 
0.168 mmol, 84% yield) as an off-white solid. mp 162-164 °C. Rf 0.37 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.56 (d, J = 4.8 Hz, 1H, HAr), 7.71 (d, J = 8.0 Hz, 
1H, HAr), 7.62 (td, J = 7.7, 1.8 Hz, 1H, HAr), 7.48-7.33 (m, 5H, HAr), 7.25-7.19 (m, 
3H, HAr), 7.18-7.12 (m, 2H, HAr), 6.47 (s, 1H, C2indoleH), 6.33 (d, J = 2.5 Hz, 1H, 
HAr), 6.12 (d, J = 2.5 Hz, 1H, HAr), 5.11 (s, 2H, OCH2), 3.56 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 167.6, 165.8, 152.9, 149.1, 143.0, 138.3, 136.3, 135.6, 129.9, 128.8 (2C), 
128.5, 127.9 (2C), 126.5, 124.6, 123.6, 122.6, 120.6, 119.9, 109.6, 109.1, 102.8, 96.4, 70.3, 33.0. 
IR νmax 2982 (m), 2902 (m), 1660 (m), 1637 (m), 1552 (m), 1431 (m), 1398 (m), 1371 (m), 1344 (m), 1244 
(m), 1197 (m), 1073 (m), 745 (s). 
HRMS calculated for C26H22N3O2
+ [M+H]+ 408.1707; Found 408.1701. 
 
3-(1-Methyl-1H-indol-3-yl)-2-(pyridin-2-yl)isoquinolin-1(2H)-one (7n) 
 
Following General Procedure D, starting from 5n and 6a, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7n (57.6 mg, 
0.164 mmol, 82% yield) as a pale yellow solid. mp 173-175 °C. Rf 0.60 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.52 (ddd, J = 4.9, 1.8, 0.7 Hz, 1H, HAr), 8.42 (d, J 
= 8.1 Hz, 1H, HAr), 7.72 (d, J = 8.0 Hz, 1H, HAr), 7.65 (ddd, J = 8.3, 7.2, 1.3 Hz, 
1H, HAr), 7.58 (td, J = 7.8, 1.9 Hz, 1H, HAr), 7.53 (d, J = 7.8 Hz, 1H, HAr), 7.45 
(ddd, J = 8.2, 7.2, 1.2 Hz, 1H, HAr), 7.22-7.09 (m, 5H, HAr), 6.77 (s, 1H, HAr), 6.56 
(s, 1H, C2indoleH), 3.57 (s, 1H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 163.9, 153.4, 149.1, 138.1, 137.5, 136.5, 136.3, 132.9, 129.7, 128.3, 127.0, 
126.5, 126.0, 125.2, 124.6, 123.4, 122.4, 120.3, 120.0, 110.1, 109.5, 108.1, 32.9. 
IR νmax 2976 (w), 2902 (w), 1655 (m), 1618 (m), 1588 (m), 1563 (m), 1471 (m), 1394 (m), 1376 (m), 1334 
(m), 1244 (m), 1130 (m), 1064 (m), 788 (m), 752 (m), 742 (s). 
HRMS calculated for C23H18N3O
+ [M+H]+ 352.1444; Found 352.1451. 
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2-(1-Methyl-1H-indol-3-yl)-4H-[1,2'-bipyridin]-4-one (7o) 
 
Following General Procedure D, starting from 5o and 6a, a purification by preparative 
TLC (DCM/MeOH 19:1) afforded the title compound 7o (34.4 mg, 0.114 mmol, 57% 
yield) as an off-white solid. mp 150-152 °C. Rf 0.34 (DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.52 (d, J = 3.9 Hz, 1H), 7.90 (d, J = 7.8 Hz, 1H), 7.43-
7.33 (m, 2H), 7.24 (d, J = 8.6 Hz, 1H), 7.20-7.13 (m, 2H), 7.02 (t, J = 7.4 Hz, 1H), 6.81 
(d, J = 8.1 Hz, 1H), 6.77 (s, 1H), 6.64 (d, J = 2.5 Hz, 1H), 6.50 (dd, J = 7.8, 2.5 Hz, 
1H), 3.68 (s, 3H). 
13C NMR (101 MHz, CDCl3) δ 179.9, 154.0, 149.2, 144.5, 140.8, 137.8, 136.6, 129.6, 
125.8, 123.2, 122.7, 121.5, 120.9, 119.9, 119.6, 117.6, 109.7, 109.3, 33.2. 
IR νmax 3056 (w), 2933 (w), 1625 (s), 1566 (s), 1547 (s), 1466 (s), 1447 (s), 1430 (s), 1277 (s), 1246 (s), 
790 (m), 740 (s). 
HRMS calculated for C19H16N3O
+ [M+H]+ 302.1288; Found 302.1284. 
 
6-(5-Bromo-1-methyl-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7q) 
 
Following General Procedure D, starting from 5a and 6b, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7q (58.0 mg, 
0.156 mmol, 76% yield) as a white solid. mp 215-217 °C. Rf 0.39 (DCM/MeOH 
19:1). 
1H NMR (400 MHz, CDCl3) δ 8.54 (d, J = 3.7 Hz, 1H, HAr), 7.79 (d, J = 1.7 Hz, 
1H, HAr), 7.64 (d, J = 1.9 Hz, 1H, HAr), 7.49 (dd, J = 9.2, 6.9 Hz, 1H, HAr), 7.28 
(dd, J = 8.7, 1.8 Hz, 1H, HAr), 7.22 (ddd, J = 7.5, 4.9, 0.9 Hz, 1H, HAr), 7.14 (d, J 
= 7.9 Hz, 1H, HAr), 7.07 (d, J = 8.7 Hz, 1H, HAr), 6.62 (dd, J = 9.2, 1.1 Hz, 1H, HAr), 6.50 (s, 1H, 
C2indoleH), 6.42 (dd, J = 6.9, 1.2 Hz, 1H, HAr), 3.55 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 164.0, 152.9, 149.2, 142.4, 140.2, 138.4, 134.9, 130.8, 128.1, 125.5, 124.1, 
123.8, 122.3, 119.2, 114.1, 111.1, 109.2, 108.0, 33.2. 
IR νmax 3093 (w), 2920 (w), 1661 (s), 1588 (s), 1548 (s), 1467 (s), 1434 (m), 1142 (m), 799 (s), 785 (s), 746 
(m), 730 (m). 
HRMS calculated for C19H14
79BrN3NaO
+ [M+Na]+ 402.0212; found 402.0210. 
 
6-(1H-Indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7r) 
 
Following General Procedure D, starting from 5a and 6c, a purification by 
preparative TLC (DCM/MeOH 19:1) afforded the title compound 7r (48.2 mg, 
0.168 mmol, 84% yield) as a pale brown solid. mp 175-177 °C. Rf 0.35 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, MeOD) δ 8.47 (ddd, J = 4.9, 1.7, 0.6 Hz, 1H, HAr), 7.78 (td, 
J = 7.8, 1.9 Hz, 1H, HAr), 7.73 (dd, J = 9.1, 7.1 Hz, 1H, HAr), 7.62 (d, J = 7.6 Hz, 
1H, HAr), 7.36 (ddd, J = 7.5, 5.0, 0.9 Hz, 1H, HAr), 7.30-7.27 (m, 2H, HAr), 7.14-
7.05 (m, 2H, HAr), 6.72-6.67 (m, 2H, HAr), 6.62 (dd, J = 9.1, 1.0 Hz, 1H, HAr). NH is not resolved in MeOD 
but could be observed at 10.45 ppm as a broad singlet in acetone-d6. 
13C NMR (101 MHz, MeOD) δ 166.2, 153.7, 149.9, 145.8, 143.1, 140.3, 137.2, 127.3, 127.2, 125.6, 125.5, 
123.5, 121.4, 120.0, 118.2, 112.6, 110.6, 110.5. 
IR νmax 3124 (br), 1641 (s), 1545 (s), 1510 (m), 1461 (m), 1431 (s), 1389 (s), 1144 (m), 1016 (m), 801 (s), 
794 (s), 739 (s). 
HRMS calculated for C18H14N3O
+ [M+H]+ 288.1131; found 288.1132.  
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6-(6-Bromo-1H-indol-3-yl)-2H-[1,2'-bipyridin]-2-one (7s) 
 
Following General Procedure D, starting from 5a and 6d, a purification by 
preparative TLC (DCM/MeOH 24:1) afforded the title compound 7s (56.2 mg, 
0.153 mmol, 77% yield) as a pale brown solid. mp 213-215 °C. Rf 0.28 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 9.66 (bs, 1H, NH), 8.44 (dd, J = 4.8, 1.1 Hz, 
1H, HAr), 7.61-7.50 (m, 2H, HAr), 7.47 (d, J = 8.6 Hz, 1H, HAr), 7.31 (d, J = 
1.5 Hz, 1H, HAr), 7.18 (dd, J = 8.6, 1.7 Hz, 1H, HAr), 7.16-7.08 (m, 1H, HAr), 7.06 (d, J = 7.9 Hz, 1H, HAr), 
6.60 (dd, J = 9.2, 1.0 Hz, 1H, HAr), 6.53 (d, J = 2.7 Hz, 1H, HAr), 6.48 (dd, J = 7.0, 1.0 Hz, 1H, HAr). 
13C NMR (101 MHz, CDCl3) δ 164.4, 152.7, 149.2, 143.2, 140.8, 138.6, 136.4, 126.5, 124.9, 124.0, 123.9, 
123.8, 120.5, 118.7, 116.1, 114.8, 110.2, 108.7. 
IR νmax 3253 (br), 1665 (s), 1585 (m), 1546 (s), 1467 (m), 1441 (m), 1104 (m), 803 (s), 788 (m). 
HRMS calculated for C18H12
79BrN3NaO
+ [M+Na]+ 388.0056; found 388.0054. 
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4. Same general procedure D for the synthesis of 8-(indol-3-yl)-quinoline N-oxides 
 
8-(1-Methyl-1H-indol-3-yl)quinoline 1-oxide (12a) 
 
Following General Procedure D, starting from quinoline N-oxide 11a and 6a, a 
purification by preparative TLC (DCM/MeOH 19:1) afforded the title compound 12a 
(32.8 mg, 0.120 mmol, 60% yield) as a yellow oil. Rf 0.80 (DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.37 (dd, J = 6.0, 1.2 Hz, 1H, HAr), 7.83 (dd, J = 8.1, 
1.6 Hz, 1H, HAr), 7.73 (dd, J = 8.5, 1.1 Hz, 1H, HAr), 7.67 (dd, J = 7.2, 1.6 Hz, 1H, 
HAr), 7.59 (dd, J = 8.0, 7.3 Hz, 1H, HAr), 7.41-7.32 (m, 2H, HAr), 7.29-7.17 (m, 2H, 
HAr), 7.12 (s, 1H, C2indoleH), 7.09 (ddd, J = 8.0, 7.0, 1.1 Hz, 1H, HAr), 3.86 (s, 3H, 
NCH3). 
13C NMR (101 MHz, CDCl3) δ 140.9, 137.2, 136.3, 135.5, 132.6, 129.3, 129.2, 127.9, 127.9, 127.3, 
125.6, 121.5, 121.0, 120.1, 119.6, 117.0, 109.3, 33.0. 
IR νmax 3051 (w), 2930 (w), 1707 (m), 1613 (w), 1570 (m), 1476 (m), 1418 (m), 1366 (m), 1302 (m), 1245 
(s), 1160 (w), 1058 (w), 1021 (w), 902 (w), 824 (m). 
HRMS calculated for C18H15N2O
+ [M+H]+ 275.1179; found 275.1188. 
 
2-Methyl-8-(1-methyl-1H-indol-3-yl)quinoline 1-oxide (12b) 
 
Following General Procedure D, starting from 2-methylquinoline N-oxide 11b  and 
6a, a purification by preparative TLC (DCM/MeOH 19:1) afforded the title 
compound 12b (38.2 mg, 0.132 mmol, 66% yield) as a yellow oil. Rf 0.85 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 7.80 (dd, J = 8.0, 1.6 Hz, 1H, HAr), 7.66-7.62 (m, 
2H, HAr), 7.54 (dd, J = 8.0, 7.3 Hz, 1H, HAr), 7.34 (m, 1H, HAr), 7.30 (m, 2H, 
HAr), 7.22 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, HAr), 7.14 (s, 1H, C2indoleH), 7.05 (ddd, J 
= 7.9, 7.0, 1.0 Hz, 1H, HAr), 3.86 (s, 3H, NCH3), 2.56 (s, 3H, CH3). 
13C NMR (101 MHz, CDCl3) δ 146.8, 140.9, 136.3, 135.6, 131.3, 129.4, 128.8, 127.9, 126.9, 126.9, 
124.5, 123.0, 121.5, 120.1, 119.3, 117.8, 109.3, 33.0, 19.4. 
IR νmax 3048 (w), 2936 (w), 2837 (w), 1665 (s), 1548 (s), 1466 (s), 1436 (m), 1362 (m), 1339 (m), 1228 
(m), 1159 (m), 1125 (m), 1033 (m), 846 (m), 804 (s), 737 (m). 
HRMS calculated for C19H17N2O
+ [M+H]+ 289.1335; found 289.1346. 
 
6-Methoxy-8-(1-methyl-1H-indol-3-yl)quinoline 1-oxide (12c) 
 
Following General Procedure D, starting from 6-methoxyquinoline N-oxide 11c and 
6a, a purification by preparative TLC (DCM/MeOH 19:1) afforded the title compound 
12c (34.9 mg, 0.115 mmol, 57% yield) as a yellow oil. Rf 0.78 (DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.22 (dd, J = 6.0, 1.2 Hz, 1H, HAr), 7.61 (dd, J = 8.4, 
1.2 Hz, 1H, HAr), 7.39 (dt, J = 7.9, 1.0 Hz, 1H, HAr), 7.34 (dt, J = 8.4, 0.9 Hz, 1H, 
HAr), 7.31 (d, J = 2.9 Hz, 1H, HAr), 7.25-7.17 (m, 2H, HAr), 7.12 (s, 1H, C2indoleH), 
7.12-7.05 (m, 2H, HAr), 3.94 (s, 3H, OCH3), 3.85 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 158.0, 136.8, 136.3, 135.4, 134.1, 131.1, 129.2, 
127.4, 126.8, 124.7, 121.6, 121.5, 120.1, 119.7, 116.7, 109.3, 106.0, 55.7, 33.0. 
IR νmax 3051 (w), 2985 (w), 1665 (m), 1609 (w), 1584 (m), 1552 (w), 1465 (w), 1436 (w), 1362 (w), 1266 
(s), 1230 (w), 1159 (w), 1126 (w), 1030 (w), 805 (w). 
HRMS calculated for C19H17N2O2
+ [M+H]+ 305.1285; found 305.1287. 
 
 
8-(1-methyl-1H-indol-3-yl)-6-phenylquinoline 1-oxide (12d) 
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Following General Procedure D, starting from 6-phenylquinoline N-oxide 11d and 6a, 
a purification by preparative TLC (DCM/MeOH 19:1) afforded the title compound 12d 
(51.3 mg, 0.146 mmol, 73% yield) as a yellow oil. Rf 0.58 (DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 8.34 (dd, J = 6.0, 1.2 Hz, 1H, HAr), 7.98 (d, J = 2.1 Hz, 
1H, HAr), 7.93 (d, J = 2.1 Hz, 1H, HAr), 7.75 (dd, J = 8.4, 1.1 Hz, 1H, HAr), 7.73-7.65 
(m, 2H, HAr), 7.46 (t, J = 7.4 Hz, 2H, HAr), 7.41 (dd, J = 8.5, 7.3 Hz, 2H, HAr), 7.34 (d, 
J = 8.2 Hz, 1H, HAr), 7.25-7.19 (m, 2H, HAr), 7.16 (s, 1H, C2indoleH), 7.12-7.05 (m, 1H, 
HAr), 3.84 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 140.2, 139.9, 138.9, 136.9, 136.2, 134.8, 132.8, 129.6, 129.1, 129.0, 
128.2, 127.4, 127.3, 125.8, 125.1, 121.4, 121.2, 120.0, 119.5, 116.7, 109.2, 32.8. 
IR νmax 3050 (w), 2975 (m), 2932 (m), 2873 (m), 1576 (m), 1478 (m), 1363 (m), 1332 (m), 1288 (m), 
1250 (m), 1231 (m), 1170 (m), 1133 (m), 1116 (m), 1060 (m), 846 (m), 797 (m), 762 (s), 736 (s). 
HRMS calculated for C24H19N2O
+ [M+H]+ 351.1492; found 351.1490.  
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5. Product modifications 
 
 
Following a modified reported procedure,10 7a (90 mg, 0.30 mmol, 1.0 equiv) was solubilized in dry 
ACN (0.6 mL) under N2. MeOTf (0.10 mL, 0.90 mmol, 3.0 equiv) was added to the mixture at 0 °C. 
The mixture was stirred 5 min at 0 °C and MeOH (3 mL) was added. NaBH3CN (94 mg, 1.5 mmol, 5.0 
equiv) was added portionwise to the solution at 0 °C. The mixture was stirred 15 min at 0 °C and then 
quenched with H2O (2 mL). The mixture was diluted with EtOAc (5 mL) and the layers were separated. 
The aqueous layer was extracted three times with EtOAc (5 mL). The organic layers were combined, 
dried over magnesium sulfate dehydrate, filtered and concentrated under reduced pressure. The crude 
residue was purified by preparative TLC using DCM/MeOH 19:1 as eluent to afforded 13 (50 mg, 0.22, 
74%) as an off-white solid. mp 217-219 °C. Rf 0.53 (DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 12.08 (s, 1H, NH), 7.96 (s, 1H, HAr), 7.89 (d, J = 8.0 Hz, 1H, HAr), 7.49 (dd, 
J = 8.9, 7.2 Hz, 1H, HAr), 7.38 (d, J = 8.1 Hz, 1H, HAr), 7.31 (t, J = 7.4 Hz, 1H, HAr), 7.23 (t, J = 7.3 Hz, 1H, 
HAr), 6.66 (d, J = 7.0 Hz, 1H, HAr), 6.39 (d, J = 8.9 Hz, 1H, HAr), 3.87 (s, 3H, NCH3). 
13C NMR (101 MHz, CDCl3) δ 165.5, 143.0, 142.1, 137.8, 130.0, 125.3, 122.8, 121.2, 119.9, 115.9, 110.2, 
109.1, 104.1, 33.5. 
IR νmax 3104 (m), 3043 (w), 2944 (br), 1650 (s), 1601 (s), 1570 (m), 1532 (m), 1460 (s), 1367 (s), 1256 (m), 
1238 (m), 1137 (m), 1101 (s), 980 (m), 894 (s), 777 (s), 736 (s), 713 (s). 
HRMS calculated for C14H13N2O
+ [M+H]+ 225.1022; found 225.1027. 
 
 
Following a reported procedure,11 12a (27.4 mg, 0.100 mmol, 1.00 equiv) was solubilized in dry DMF 
(3 mL). TFAA (140 µL, 1.00 mmol, 10.0 equiv) was added to the mixture at rt. The mixture was stirred 
overnight and the TFAA excess was eliminated under reduced pressure. The mixture was poured into 
H2O (30 mL) and extracted three times with EtOAc (10 mL). The organic layers were combined, 
washed twice with brine (5 mL), dried over magnesium sulfate dehydrate, filtered and concentrated 
under reduced pressure. The crude residue was purified by preparative TLC using DCM/MeOH 24:1 
as eluent to afforded 14 (17.0 mg, 0.062 mmol, 62%) as a pale brown solid. mp 192-194 °C. Rf 0.92 
(DCM/MeOH 19:1). 
1H NMR (400 MHz, CDCl3) δ 9.03 (s, 1H, NH), 7.83 (d, J = 9.5 Hz, 1H, HAr), 7.61-7.54 (m, 2H, HAr), 7.45 
(t, J = 7.4 Hz, 2H, HAr), 7.36-7.31 (m, 1H, HAr), 7.30 (d, J = 7.7 Hz, 1H, HAr), 7.23 (s, 1H, C2indoleH), 7.20-
7.15 (m, 1H, HAr), 6.66 (d, J = 9.5 Hz, 1H, HAr), 3.91 (s, 3H, NCH3). 13C NMR (101 MHz, CDCl3) δ 162.6, 
141.2, 137.4, 136.4, 132.4, 127.9, 127.0, 126.8, 123.0, 122.5, 122.0, 121.8, 120.7, 120.1, 119.5, 110.0, 
109.5, 33.3. Spectra data matched with the values reported in literature.7  
                                                   
10 Smout, V.; Peschiulli, A.; Verbeeck, S.; Mitchell, E. A.; Herrebout, W.; Bultinck, P.; Vande Velde, C. M. L.; 
Berthelot, D.; Meerpoel, L.; Maes, B. U. W. J. Org. Chem. 2013, 78, 9803–9814. 
11 Konno, K.; Hashimoto, K.; Shirahama, H.; Matsumoto, T. Heterocycles 1986, 24, 2169–2172. 
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6. Spectra of new compounds 
 
 
   
S21 
 
 
 
S22 
 
 
 
 
 
S23 
 
 
 
 
 
S24 
 
 
 
 
  
S25 
 
 
 
 
 
S26 
 
 
  
S27 
 
 
 
 
  
S28 
 
 
 
 
 
S29 
 
 
 
 
 
S30 
 
 
  
S31 
 
 
 
 
 
S32 
 
 
  
S33 
 
 
 
 
 
S34 
 
 
 
 
 
S35 
 
  
S36 
 
 
 
 
  
S37 
 
 
 
 
 
S38 
 
 
 
 
 
S39 
 
 
 
 
  
S40 
 
 
 
 
  
S41 
 
 
 
 
 
S42 
 
 
 
 
 
S43 
 
 
 
 
 
S44 
 
 
 
 
 
S45 
 
 
 
 
  
S46 
 
 
 
 
 
